Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.

Second, Kondoh and colleagues described that patients in the rhTM arm trended toward poorer 90-day survival than those in the non-rhTM arm with a marginal significance (rate difference for survival, −16.7% [95% confidence interval (CI), −33.8% to 0.4%]; odds ratio [OR] for survival, 0.32 [95% CI, 0.09 to 1.11]; P = 0.086) ( 1 ), although many previous observational studies reported that rhTM benefits AE-IPF survival ( 3 – 6 ).

also in 5,069 other papers